Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Vom Dorp

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancerTibor Szarvas, Tobias Jäger, Martin Tötsch, et al.
Cellular Signalling|May 26, 2004
Inhibition of phospholipase C-epsilon by Gi-coupled receptorsFrank vom Dorp, Aysegül Y Sari, Harald Sanders, et al.
Pathology Oncology Research : POR|January 22, 2011
Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancerTibor Szarvas, Tobias Jäger, Markus Becker, et al.
International Journal of Cancer|August 5, 2011
Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancerTibor Szarvas, Viktória László, Frank Vom Dorp, et al.
Urology|May 22, 2012
Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancerTibor Szarvas, Tobias Jäger, Viktoria Laszlo, et al.
International Journal of Cancer|March 12, 2014
Prognostic value of tissue and circulating levels of IMP3 in prostate cancerTibor Szarvas, Stephan Tschirdewahn, Christian Niedworok, et al.
The Prostate|April 11, 2016
Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancerTibor Szarvas, Henning Reis, Frank Vom Dorp, et al.
Human Pathology|March 25, 2014
Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancerTibor Szarvas, Henning Reis, Gero Kramer, et al.
BJU International|September 10, 2010
Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancerTibor Szarvas, Bernhard B Singer, Markus Becker, et al.
Plos One|November 14, 2013
Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancerChristian Niedworok, Katharina Röck, Inga Kretschmer, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancerTibor Szarvas, Tobias Jäger, Martin Tötsch, et al.
Cellular Signalling|May 26, 2004
Inhibition of phospholipase C-epsilon by Gi-coupled receptorsFrank vom Dorp, Aysegül Y Sari, Harald Sanders, et al.
Pathology Oncology Research : POR|January 22, 2011
Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancerTibor Szarvas, Tobias Jäger, Markus Becker, et al.
International Journal of Cancer|August 5, 2011
Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancerTibor Szarvas, Viktória László, Frank Vom Dorp, et al.
Urology|May 22, 2012
Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancerTibor Szarvas, Tobias Jäger, Viktoria Laszlo, et al.
International Journal of Cancer|March 12, 2014
Prognostic value of tissue and circulating levels of IMP3 in prostate cancerTibor Szarvas, Stephan Tschirdewahn, Christian Niedworok, et al.
The Prostate|April 11, 2016
Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancerTibor Szarvas, Henning Reis, Frank Vom Dorp, et al.
Human Pathology|March 25, 2014
Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancerTibor Szarvas, Henning Reis, Gero Kramer, et al.
BJU International|September 10, 2010
Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancerTibor Szarvas, Bernhard B Singer, Markus Becker, et al.
Plos One|November 14, 2013
Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancerChristian Niedworok, Katharina Röck, Inga Kretschmer, et al.
Pageof 4